Kanya Rajangam
2024 - Senti Biosciences
In 2024, Kanya Rajangam earned a total compensation of $627.7K as President, Head of Research and Development and Chief Medical Officer at Senti Biosciences, a 27% decrease compared to previous year.
Compensation breakdown
| Option Awards | $52,701 |
|---|---|
| Salary | $526,789 |
| Stock Awards | $46,460 |
| Other | $1,756 |
| Total | $627,707 |
Rajangam received $526.8K in salary, accounting for 84% of the total pay in 2024.
Rajangam also received $52.7K in option awards, $46.5K in stock awards and $1.8K in other compensation.
Rankings
In 2024, Kanya Rajangam's compensation ranked 113th out of 244 executives tracked by ExecPay. In other words, Rajangam earned more than 53.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 113 out of 244 | 54th |
Division Manufacturing | 47 out of 108 | 57th |
Major group Chemicals And Allied Products | 21 out of 44 | 52nd |
Industry group Drugs | 21 out of 41 | 49th |
Industry Biological Products, Except Diagnostic Substances | 3 out of 6 | 50th |
Source: SEC filing on January 27, 2025.
Rajangam's colleagues
We found two more compensation records of executives who worked with Kanya Rajangam at Senti Biosciences in 2024.